4-(甲氧甲酰基)-3-甲基苯甲酸 | 116934-87-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(甲氧甲酰基)-3-甲基苯甲酸
• 英文名称: 4-(methoxycarbonyl)-3-methylbenzoic acid
• 英文别名: 2-methylterephthalic acid 1-methyl ester；2-methylbenzene-1,4-dicarboxylic acid 1-methyl ester；methyl-terephthalic acid-1-methyl ester；Methyl-terephthalsaeure-1-methylester；4-methoxycarbonyl-3-methylbenzoic acid
• CAS: 116934-87-3
• 化学式: C₁₀H₁₀O₄
• 分子量: 194.187
• InChiKey: HFCRSABBNBNZNG-UHFFFAOYSA-N

物化性质

• 沸点：
  333.2±30.0 °C(Predicted)
• 密度：
  1.243±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(甲氧甲酰基)-3-甲基苯甲酸 在 borane tetrahydrofuran 、 ice 、 盐酸 、 乙酸乙酯 、 羟基甲酸酯 、 Brine 、 magnesium sulfate 作用下， 以 四氢呋喃 为溶剂， 以to give methyl 4-(hydroxymethyl)-2-methylbenzoate的产率得到methyl 4-(hydroxymethyl)-2-methylbenzoate
  参考文献：
  名称：

  PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING

  摘要：

  本发明提供了一种新型的刺猬信号抑制剂，其可用作治疗恶性肿瘤的治疗剂，其中化合物具有一般式I，其中A、X、Y、R1、R2、R3、R4、m和n如本文所述。

  公开号：

  US20090281089A1
• 作为产物：
  描述：

  2-甲基-1,4-苯二甲酸二甲酯 生成 4-(甲氧甲酰基)-3-甲基苯甲酸
  参考文献：
  名称：

  Wegscheider, Priv.-Mitt.

  摘要：

  DOI：

文献信息

• Dehydroamino acids
  申请人：——

  公开号：US20020161237A1

  公开（公告）日：2002-10-31

  Compounds of formula 1 and 1-1, 1 wherein R 1 is hydrogen, hydroxy, amino or halogen, R 2 is hydrogen, hydroxy, or halogen and R 3 is hydrogen (Formula 1) or R 1 is hydrogen and R 2 and R 3 taken together with the ethenylene group connecting them form phenyl, pyrrole, pyrroline, oxopyrroline, pyrazole, triazole, or imidazole (Formula 1-1), A is 2 R 4 R 5 are hydrogen, methyl, ethyl or halogen except that R 4 r 5 cannot both be hydrogen; and 1) B is hydrogen, or lower alkyl; or 2) B is 3 where R 6 R 7 R 8 and R 9 are independently hydrogen, hydroxy, aminosulfonyl, halogen, lower alkoxy, cyano, amino, lower alkyl, lower alkyl amino, or nitro; or 3) B is 4 where R 10 is hydrogen, hydroxy, halogen, or lower alkyl and C is a five- or six- membered ring with 0 to 3 heteroatoms which heteroatoms are selected from nitrogen, oxygen, and sulfur, which ring may be unsubstituted or mono- or di- substituted with lower alkyl, cycloalkyl, amino, or substituted amino; 4) B is 5 where X and Y are independently methylene or nitrogen; or 5) B is 6 where at leat one of T, U, V, or W is nitrogen, and any of T, U, V or W which is carbon may be substituted with lower alkyl, lower alkyl amino, lower alkoxy, hydroxy, aminosulfonyl, halogen, cyano, amino, or nitro; or 6) B is 7 where Y is carbon or nitrogen; or 7) B is a five-membered aromatic ring with 1 to 3 heteratoms selected from nitrogen, oxygen, and sulfur which ring may be unsubstituted or mono- or di-substituted with lower alkyl, cycloalky, trifluoroloweralkyl, amino, halogen, substituted amino, or which ring may be fused with a 5 or 6 membered aromatic ring containing 0 to 3 heteroatoms which heteroatoms are selected from nitrogen, oxygen, and sulfur; and pharmaceutically acceptable salts thereof, and related prodrugs, pharmaceutical compositions and methods of treatment, which compounds are useful for treating psoriasis.

  式1和1-1的化合物， 其中R1是氢，羟基，氨基或卤素，R2是氢，羟基或卤素，R3是氢（式1）或R1是氢，R2和R3连同连接它们的乙烯基团形成苯基，吡咯，吡咯烯，氧代吡咯烯，吡唑，三唑或咪唑（式1-1），A是 R4R5是氢，甲基，乙基或卤素，但R4R5不能同时为氢；和 1）B是氢或低碳烷基；或 2）B是 R6R7R8和R9独立地是氢，羟基，氨基磺酰基，卤素，低烷氧基，氰基，氨基，低烷基，低烷基氨基或硝基； 或3）B是 R10是氢，羟基，卤素或低碳烷基，C是具有0到3个异原子的五元或六元环，这些异原子选自氮，氧和硫，该环可以未取代或单取代或双取代为低烷基，环烷基，氨基或取代氨基； 4）B是 X和Y独立地是亚甲基或氮；或 5）B是 至少T，U，V或W中的一个是氮，任何是碳的T，U，V或W可以被低烷基，低烷基氨基，低烷氧基，羟基，氨基磺酰基，卤素，氰基，氨基或硝基取代；或 6）B是 Y是碳或氮； 或 7）B是具有1到3个异原子的氮，氧和硫中选择的五元芳香环，该环可以未取代或单取代或双取代为低烷基，环烷基，三氟低烷基，氨基，卤素，取代氨基，或该环可以与含有0到3个异原子的五元或六元芳香环融合，这些异原子选自氮，氧和硫；及其药学上可接受的盐，相关的前药，药物组合物和治疗方法，这些化合物对治疗牛皮癣有用。
• DNA‐Encoded Libraries: Hydrazide as a Pluripotent Precursor for On‐DNA Synthesis of Various Azole Derivatives
  作者：Fei Ma、Jie Li、Shuning Zhang、Yuang Gu、Tingting Tan、Wanting Chen、Shuyue Wang、Peixiang Ma、Hongtao Xu、Guang Yang、Richard A. Lerner

  DOI：10.1002/chem.202100850

  日期：2021.6

  chemical transformation strategy using DNA-conjugated benzoyl hydrazine as a common versatile precursor in azole chemical expansion of DELs. DNA-compatible reactions deriving from the common benzoyl hydrazine precursor showed excellent functional group tolerance with exceptional efficiency in the synthesis of various azoles, including oxadiazoles, thiadiazoles, and triazoles, under mild reaction conditions

  DNA 编码的组合化学文库 (DEL) 技术是一种结合遗传学和化学力量的方法，已成为药物发现的宝贵工具。骨骼多样性在 DEL 应用中起着至关重要的作用，并且在很大程度上依赖于新的 DNA 兼容化学反应。我们在此报告了一种系统发育化学转化策略，该策略使用 DNA 共轭苯甲酰肼作为 DEL 的唑类化学扩展中的通用前体。源自常见苯甲酰肼前体的 DNA 相容反应显示出优异的官能团耐受性，在温和的反应条件下合成各种唑类（包括恶二唑、噻二唑和三唑）时具有出色的效率。
• Diaminopropionic acid derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06331640B1

  公开（公告）日：2001-12-18

  A compound of formula 1a which is useful for treating reperfusion injury, and salts, prodrugs, and related compounds.

  一种用于治疗再灌注损伤的化合物1a及其盐、前药和相关化合物。
• [EN] BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARβ) AGONISTS<br/>[FR] COMPOSÉS DE TYPE ACIDE BICYCLOHÉTÉROARYL-HÉTÉROARYL-BENZOÏQUE UTILISÉS COMME AGONISTES DE RÉCEPTEURS BÊTA DE L'ACIDE RÉTINOÏQUE (RARΒ)
  申请人：KING S COLLEGE LONDON

  公开号：WO2016097004A1

  公开（公告）日：2016-06-23

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicycloheteroaryl-heteroaryl-benzoic acid compounds of the following formula (for convenience, collectively referred to herein as "BHBA compounds"), which, inter alia, are (selective) retinoic acid receptor beta (RARβ) (e.g., RARβ2) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RARβ (e.g., RARβ2), to cause or promote neurite development, neurite outgrowth, and/or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RARβ (e.g., RARβ2), that are ameliorated by the activation of RARβ (e.g., RARβ2), etc., including, e.g., neurological injuries such as spinal cord injuries.

  本发明涉及治疗化合物领域，更具体地涉及以下公式的某些双环杂环芳基-杂环芳基-苯甲酸化合物（为方便起见，统称为“BHBA化合物”），它们是（选择性）视黄酸受体β（RARβ）（例如，RARβ2）激动剂。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在体内外（选择性）激活RARβ（例如，RARβ2），导致或促进神经突起发育、神经突起和/或神经再生，以及治疗由RARβ（例如，RARβ2）介导的疾病和症状，通过RARβ（例如，RARβ2）激活而得到改善等，包括神经损伤如脊髓损伤。
• [EN] TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS<br/>[FR] COMPOSÉS TRIAZOLONE UTILISÉS COMME INHIBITEURS DE LA MPGES-1
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2013186692A1

  公开（公告）日：2013-12-19

  The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

  本公开涉及式(I)的化合物及其药用盐，作为mPGES-1抑制剂。这些化合物是微粒体前列腺素E合成酶-1（mPGES-1）酶的抑制剂，因此在治疗来自各种疾病或病况的疼痛和/或炎症方面具有用处，如哮喘、骨关节炎、类风湿关节炎、急性或慢性疼痛和神经退行性疾病。